ASX Announcement **20 November 2026**

Resignation of Non-executive Director

Genetic Signatures Limited (ASX:GSS) ("**Genetic Signatures**" or "the **Company**") advises that Dr Jenny Harry has tendered her resignation as a Non-Executive Director of the Company, effective 20 November 2026.

In light of recent developments at Genetic Signatures, Dr Harry believes this is the right time for her to step aside. She is thankful for the opportunity to have served on the Board of Genetic Signatures and wishes the Company success for the future.

Chair, Mike Aicher, said:

"On behalf of the Board, I would like to thank Jenny for her contribution to Genetic Signatures over the past two years. Jenny has been a valued member of the Board, and we thank her for her dedication and service to the Company. We wish Jenny all the very best for the future."

This announcement has been authorised for release by the Board of Directors of Genetic Signatures Limited.

– END –

For further information contact:

Mike Aicher
Chair
Genetic Signatures
info@geneticsignatures.com

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580

Rule 3.19A.3

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**Genetic Signatures Limited**
ABN	**30 095 913 205**

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Dr Jenny Harry
Date of last notice	24 November 2025
Date that director ceased to be director	20 November 2026

Part 1 – Director's relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
NA

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	**Number & class of securities**
Dermochelys Pty Ltd<CMYDAS Superannuation Fund A/C> (Beneficiary)	250,000 Restricted Rights

Part 3 – Director's interests in contracts

Detail of contract	NA
Nature of interest	NA
Name of registered holder (if issued securities)	NA
No. and class of securities to which interest relates	NA

+ See chapter 19 for defined terms.